Efficacy and Safety of Dapagliflozin in HFrEF According to NT-proBNP
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Circulation: Heart Failure
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial
Circ Heart Fail 2021 Nov 22;[EPub Ahead of Print], JH Butt, C Adamson, KF Docherty, RA de Boer, MC Petrie, SE Inzucchi, MN Kosiborod, A Maria Langkilde, D Lindholm, FA Martinez, O Bengtsson, M Schou, E O'Meara, P Ponikowski, MS Sabatine, M Sjöstrand, SD Solomon, PS Jhund, JJV McMurray, L KøberFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.